SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001438533-20-000036
Filing Date
2020-11-16
Accepted
2020-11-16 16:04:51
Documents
16
Period of Report
2020-11-13
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rtrx-20201113.htm   iXBRL 8-K 46376
2 EX-3.1 ex2020161131.htm EX-3.1 108949
3 EX-3.2 ex2020161132.htm EX-3.2 9857
  Complete submission text file 0001438533-20-000036.txt   391242

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rtrx-20201113.xsd EX-101.SCH 2498
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rtrx-20201113_cal.xml EX-101.CAL 781
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rtrx-20201113_def.xml EX-101.DEF 17387
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rtrx-20201113_lab.xml EX-101.LAB 34508
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rtrx-20201113_pre.xml EX-101.PRE 18486
9 EXTRACTED XBRL INSTANCE DOCUMENT rtrx-20201113_htm.xml XML 14940
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 201316709
SIC: 2834 Pharmaceutical Preparations